Literature DB >> 16259654

Outcome following retrosigmoid microvascular decompression of the facial nerve for hemifacial spasm.

D A Moffat1, V S P Durvasula, A Stevens King, R De, D G Hardy.   

Abstract

This paper evaluates the outcome of retrosigmoid microvascular decompression of the facial nerve in a series of patients suffering from hemifacial spasm who had been referred to the skull-base team (comprising senior authors DAM and DGH). The paper is a retrospective review of 15 patients who underwent retrosigmoid microvascular decompression of the facial nerve at Addenbrooke's Hospital between 1985 and 1995. In this series it was possible to obtain complete resolution of hemifacial spasm in 93.3 per cent of cases in the short term and in 80 per cent in the long term. Twelve patients (80 per cent) were symptom-free post-operatively. Two patients had minor recurrence of symptoms occurring within six months of the procedure. One patient with no identifiable vascular impingement of the facial nerve had no improvement following surgery. Three patients suffered sensorineural hearing loss. Two patients complained of post-operative tinnitus, and transient facial palsy was noted in one patient. Retrosigmoid microvascular decompression of the facial nerve provides excellent long-term symptom control in a high percentage of patients with hemifacial spasm.

Entities:  

Mesh:

Year:  2005        PMID: 16259654     DOI: 10.1258/002221505774481255

Source DB:  PubMed          Journal:  J Laryngol Otol        ISSN: 0022-2151            Impact factor:   1.469


  2 in total

1.  Prognostic factors of hemifacial spasm after microvascular decompression.

Authors:  Hong Rae Kim; Deok-Joo Rhee; Doo-Sik Kong; Kwan Park
Journal:  J Korean Neurosurg Soc       Date:  2009-06-30

Review 2.  Hearing Loss following Posterior Fossa Microvascular Decompression: A Systematic Review.

Authors:  Matthew Bartindale; Matthew Kircher; William Adams; Neelam Balasubramanian; Jeffrey Liles; Jason Bell; John Leonetti
Journal:  Otolaryngol Head Neck Surg       Date:  2017-09-12       Impact factor: 3.497

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.